Aim: To evaluate treatment data from DISCOVER (NCT02322762 and NCT02226822), a global, prospective, observational study programme of patients with type 2 diabetes initiating a second-line glucose-lowering therapy.
| INTRODUCTION
Optimal glycaemic control, along with the management of comorbidities such as hypertension and hyperlipidaemia, and prevention of long-term complications, remains the cornerstone of the management of patients with type 2 diabetes. Current clinical guidelines recommend an HbA 1c target of less than 7.0% (53 mmol/mol) for most patients. [1] [2] [3] [4] [5] To achieve this target, most guidelines recommend the use of metformin in conjunction with diet and lifestyle modifications as first-line therapy. When metformin monotherapy fails to control glycaemic levels, a second glucose-lowering drug should be added to metformin in a timely fashion (within 3-6 months of an HbA 1c value above target). [1] [2] [3] [4] [5] The Japanese guidelines take a different approach and recommend monotherapy (metformin or other) in conjunction with medical nutrition therapy as first-line pharmacological treatment;
the choice of first-line glucose-lowering agent should be tailored to the patient's characteristics and metformin is not recommended over any other agent. 6 Although guidelines suggest using a personalized approach to select second-line therapy based on patient characteristics (e.g. duration of diabetes, presence of co-morbidities, age and risk of hypoglycaemia), only the consensus report by the American Diabetes Association and the European Association for the Study of Diabetes provides a clear treatment algorithm based on the presence of atherosclerotic cardiovascular disease or chronic kidney disease. 5 The wide variety of glucose-lowering drug classes available as possible second-line therapies results in difficult treatment decisions for clinicians. DISCOVER is a 3-year, global programme of observational research conducted in 38 countries, assessing the treatment of patients with type 2 diabetes in routine clinical practice. 7 The primary objective of the study is to describe global disease management patterns and associated clinical outcomes in people with type 2 diabetes initiating a second-line glucose-lowering therapy. In many of the included countries, data are currently scarce or non-existent. Here, we report patterns of treatment changes from first to second line at the start of the study in the overall patient population, and assess factors associated with choice of second-line therapy in the subset of patients who were prescribed metformin monotherapy as first-line treatment.
Malaysia, South Korea and Taiwan). The study protocols were approved by the relevant clinical research ethics committees in each country and institutional review boards at each site, and complied with the Declaration of Helsinki, the International Conference on Harmonization of Good Clinical Practice, and the local regulations for clinical research.
| Site and investigator selection
For each participating country, the characteristics of physicians and clinical centres involved in the management of people with type 2 diabetes were assessed before the start of the study by conducting literature searches and interviewing key local diabetes experts who acted as national coordinating investigators. 9 Information on the proportions of different types of practices (primary care centres, specialized diabetes centres and different types of hospitals) and physicians (primary care physicians, diabetologists/endocrinologists, cardiologists and other specialist physicians) treating patients with type 2 diabetes were collated. A list of sites that would match these characteristics as closely as possible was established for each country, and these sites were invited to participate. Among the invited sites, approximately one-third were able to take part and subsequently recruited patients into the study.
| Patient enrolment
Inclusion and exclusion criteria were kept to a minimum to reflect the diversity of patients treated in routine clinical practice. Briefly, patients older than 18 years of age who had type 2 diabetes and who were initiating a second-line glucose-lowering therapy (add-on or switch, including switching between two agents in the same class) were eligible for inclusion if: they were not pregnant; they were not undergoing dialysis; they did not have a history of renal transplant;
and their first-line therapy was not an injectable agent, a herbal remedy alone or natural medicine alone. Full inclusion and exclusion criteria can be found in Table S1 . Of note, J-DISCOVER enrolled only patients who were receiving oral monotherapy as first-line treatment, whereas DISCOVER enrolled patients who were receiving any type of oral therapy (one or more oral agents, or a fixed dose combination).
The study protocol stated that participating physicians should invite consecutive eligible patients to enrol in the study. All participating patients provided signed informed consent. DISCOVER recruited patients from December 2014 to June 2016; J-DISCOVER recruited patients from September 2014 to December 2015.
| Data collection
Data were collected using a standardized electronic case report form and were transferred to a central database via a web-based data capture system. Some data were extracted from existing electronic health records in Canada, Denmark, France, Norway and Sweden; in these countries, an abbreviated case report form was used. All data not automatically extracted from electronic medical records were manually transferred from existing medical records (electronic or otherwise) to the web-based data capture system by the participating physicians. To ensure data quality, a risk-based monitoring model was implemented.
On-site visits were organized at each data collection time point, and key variables entered into the web-based data capture system were checked against the original medical records for a random sample of were not adjudicated and relied on the judgement of the participating physicians. Reasons for changing first-line therapy and reasons for choosing second-line therapy were entered in the data capture system by the participating physicians, who selected one or several reasons from predefined lists.
| Statistical analysis
For the present analysis, patients from China (n = 1293) were excluded because complete data were not available at the time of publication. Patients were also excluded if they had treatment information missing in the database (n = 4), or if they had metformin monotherapy recorded as both first-and second-line therapy (n = 27). The total number of patients included in the analysis was therefore 14 668
(91.7% of the total DISCOVER population). Descriptive data are presented as numbers and percentages for categorical variables; mean (standard deviation) values are reported for continuous variables.
Factors associated with choice of second-line therapy were exclusively assessed in participants who were receiving metformin monotherapy at first line, to increase homogeneity and eliminate differences in choice of second-line therapy because of differences in first-line therapy. Conventional logistic regression was deemed inappropriate to assess these associations because some second-line therapies were prescribed to small numbers of patients. In such cases, the maximum likelihood estimates used in the logistic regression model may be biased. Firth logistic regression models were used instead because they are based on penalized likelihood, which corrects the small-sample bias. 10, 11 Based on the five most prescribed second-line dual therapies after first-line metformin monotherapy, four models were run testing: (a) likelihood of prescribing a dipeptidyl peptidase-4 (DPP-4) inhibitor relative to a sulphonylurea (SU), in combination with metformin, (b) likelihood of prescribing a sodium-glucose co-transporter-2 (SGLT-2) inhibitor relative to an SU, in combination with metformin, (c) likelihood of prescribing insulin relative to an SU, in 
| RESULTS

| Baseline patient characteristics
| Treatment patterns
Patients' first-line therapies and changes to second-line therapy for the overall population are presented in Table 2 ; first-and second-line therapies by region have been presented elsewhere. 12 
| Factors associated with second-line treatment choices in patients prescribed metformin monotherapy as first-line treatment
The baseline characteristics of the subset of participants who received metformin monotherapy at first line (n = 8488), and in which the factors associated with second-line treatment choices were assessed, are shown in Table S2 . Of note, mean HbA 1c level was considerably higher in patients prescribed insulin in combination with metformin at second line than in other groups of patients (10.2% vs. 7.9%-8.5%; Table S2 ). Lack of efficacy was the most commonly stated reason for changing therapy in all treatment groups (72.8%-93.7%), but adverse effects were more commonly reported as the reason for changing treatment in the group of patients who discontinued metformin at second line (n = 1194) than among other patient groups (20.0% vs. 2.2%-3.9%; Table S3 ). Overall, expected efficacy was the most commonly stated reason for choosing second-line therapies (63.2%),
and weight was often stated as a reason for choosing combinations of metformin with an SGLT-2 inhibitor or a GLP-1 receptor agonist (59.9% and 85.2%, respectively; Table S3 ).
T A B L E 2 Choice of second-line glucose-lowering therapy, overall and according to first-line therapy Variations in the choice of second-line therapy according to region are shown in Expected efficacy was the most commonly stated reason for choosing second-line therapies in all regions (43.4%-88.6%; Table S5 ). In Africa, access, convenience and cost were also commonly selected reasons for choosing a second-line therapy (17.4%, 14.0% and 11.8%, respectively), whereas tolerability, weight and hypoglycaemia were common factors in Europe (28.9%, 28.9% and 26.9%, respectively).
The results of the Firth logistic regression models assessing the factors associated with second-line treatment choices are shown in 10 BMI, body mass index; CI, confidence interval; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MET, metformin; OR, odds ratio; PCP, primary care physician; SGLT-2i, sodium-glucose co-transporter-2 inhibitor; SU, sulphonylurea. a Composite of nephropathy, retinopathy and neuropathy. b Composite of coronary heart disease, cerebrovascular disease, peripheral artery disease, heart failure and implantable cardioverter defibrillator use. c Hypoglycaemic events requiring external/third-party assistance in the previous year. d Hypoglycaemic events that were self-reported and non-confirmed, and which occurred in the previous 4 weeks. e Odds ratio was not estimated because none of the patients in Africa received an SGLT-2i they were older than 65 years of age (relative to <65 years of age); they had a longer duration of education (>13 years relative to none, 1-6 years or 7-13 years); they had an HbA 1c level less than 7.0% (relative to 8.0% to <9.0% and ≥ 9.0%); they had health insurance; they had not experienced a minor hypoglycaemic event in the previous 4 weeks; and the second-line therapy was prescribed by a specialist physician (relative to a primary care physician). Patients in Europe were more likely than patients in Africa, the Americas, South-East Asia or the Western Pacific region to be prescribed a DPP-4 inhibitor relative to an SU, in combination with metformin.
| Likelihood of prescribing an SGLT-2 inhibitor relative to an SU, in combination with metformin
Factors significantly associated with having an increased likelihood of receiving an SGLT-2 inhibitor relative to an SU in combination with metformin included: being 65-74 years of age (relative to being <65 years of age); increasing BMI (per 5 kg/m 2 increment); being employed or self-employed (relative to not being employed); having health insurance coverage; and being prescribed a second-line therapy by a diabetologist/endocrinologist (relative to a primary care physician). Conversely, factors significantly associated with having a lower likelihood of receiving an SGLT-2 inhibitor relative to an SU in combination with metformin included: having less education (none, 1-6 years or 7-13 years, relative to >13 years); having an HbA 1c level of at least 9.0% (relative to <7.0%); and having a medical history of macrovascular complications or chronic kidney disease (relative to having no such medical history). In all regions, compared with Europe, treatment with an SU in combination with metformin was more likely than treatment with an SGLT-2 inhibitor in combination with metformin (odds ratios could not be calculated for the likelihood of receiving an SGLT-2 inhibitor relative to an SU in Africa because no patients in this region received an SGLT-2 inhibitor) (Table S4 ).
| Likelihood of prescribing insulin relative to an SU, in combination with metformin
Patients were more likely to be prescribed insulin than an SU in combination with metformin if: they had a longer time since diagnosis of diabetes (per 6-month increment); they had an HbA 1c level of at least 9.0% (relative to <7.0%); they had experienced a major hypoglycaemic event in the previous year; and the second-line therapy was prescribed by a diabetologist or endocrinologist (relative to a primary care physician). In all regions, compared with Europe, treatment with an SU was more likely than treatment with insulin in combination with metformin.
| Likelihood of prescribing a GLP-1 receptor agonist relative to an SU, in combination with metformin
Factors significantly associated with having an increased likelihood of receiving a GLP-1 receptor agonist relative to an SU in combination with metformin included: increasing BMI (per 5 kg/m 2 increment); being employed or self-employed (relative to not being employed); and being prescribed a second-line therapy by a diabetologist/endocrinologist (relative to a primary care physician). Conversely, factors significantly associated with having a lower likelihood of receiving a GLP-1 receptor agonist relative to an SU in combination with metformin included: having less education (1-6 years or 7-13 years, relative to >13 years). In all regions, compared with Europe, treatment with an SU in combination with metformin was more likely than treatment with a GLP-1 receptor agonist in combination with metformin.
| DISCUSSION
This study provides important new global data on the treatment of people with type 2 diabetes initiating a second-line glucose-lowering therapy. Despite guideline recommendations that metformin monotherapy should be used as first-line therapy in most patients, [1] [2] [3] [4] [5] approximately a fifth of participants were not recorded as having received metformin at first line, either alone or in combination with another agent. SUs were widely used at both first and second line, as were DPP-4 inhibitors, whereas, at second line, only 4.3% of patients received an SGLT-2 inhibitor in combination with metformin, and only 1.3% received a GLP-1 receptor agonist in combination with metformin. For patients who received metformin monotherapy at first line, the most commonly prescribed second-line therapies were an SU or a DPP-4 inhibitor in addition to metformin. Just under 15% of these patients discontinued metformin at second line. These results are in line with findings from a population-based, observational study conducted in five European countries, 13 which showed that metformin monotherapy was the most commonly prescribed first-line treatment (65%-88% of patients). In these patients, the most common secondline therapies were combinations of metformin with either an SU or a DPP-4 inhibitor.
The relatively high proportion of DISCOVER patients who received first-line treatment with a combination therapy rather than metformin monotherapy could reflect country-specific treatment practices, or could be a result of late diagnosis of diabetes following the recommendation to use combination therapies in patients with an HbA 1c level of at least 7.5% when the diagnosis of type 2 diabetes is established. 1 Among patients who were not prescribed metformin, either alone or in combination at first line, explanations could include contraindications, such as chronic kidney disease, or physician preference for treatment with SUs or DPP-4 inhibitors. A survey conducted in 2016 by the International Diabetes Federation and a recent epidemiological study also suggest that the availability of metformin is suboptimal in some low-to medium-income countries. 14, 15 Of note, more than 1 in 10 patients who received a monotherapy as first-line treatment switched to another monotherapy when initiating second-line treatment. This appears to be counter to clinical guidelines, which recommend the addition of a glucose-lowering agent when monotherapy fails to control glycaemia. [1] [2] [3] [4] [5] It should be noted, however, that some of these cases might reflect patients changing treatment because of poor tolerability or affordability reasons rather than a lack of efficacy. Among patients who received metformin monotherapy at first line and who subsequently discontinued metformin at second line, the reason stated for changing first-line therapy was lack of efficacy in approximately 75%, and adverse effects in 20%. The use of SGLT-2 inhibitors and GLP-1 receptor agonists may become more common given recent evidence from several cardiovascular outcomes trials and a large international observational study that these classes of drugs reduce cardiovascular event rates in patients at high cardiovascular risk, [16] [17] [18] [19] [20] [21] and the recommendation in recent guidelines to use these drugs in patients with established cardiovascular disease or chronic kidney disease. 5 In the multivariate analyses of factors associated with second-line treatment choices among patients receiving metformin monotherapy at first line, lower education increased the likelihood of SU prescription relative to DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 receptor agonists. This may reflect lower socioeconomic status and fewer economic resources of these people, leading to the prescription of more affordable drugs. These findings are in line with recent guidelines from WHO, which recommends the use of SUs as second-line treatment in settings with limited health system resources. 22 Furthermore, being employed or self-employed, relative to being disabled, not working or retired, was also associated with an increased likelihood of being prescribed an SGLT-2 inhibitor or a GLP-1 receptor agonist relative to an SU; again, likely to be related to the cost of treatment. Having an HbA 1c level of at least 9.0% was a predictor of SU prescription in addition to metformin, relative to DPP-4 or SGLT-2 inhibitors. This may reflect the high 6-month efficacy of SUs, 23, 24 leading to their use for rapid glycaemic control in patients with the most severely elevated blood glucose levels. Our analysis also showed a significant association between physician's specialty and second-line therapy prescription after first-line metformin monotherapy. Endocrinologists and diabetologists were more likely to prescribe a DPP-4 inhibitor, an SGLT-2 inhibitor, insulin or a GLP-1 receptor agonist than an SU, relative to primary care physicians. These findings suggest that prescription preferences may differ in primary care physicians and specialist physicians. Indeed, a recent survey in Japan highlighted that specialists and non-specialists considered different factors when selecting first-line therapy, 25 which may also apply to second-line treatment choices. However, such findings may not be generalizable to other countries, and our results may reflect the fact that patients with more severe disease, for whom these drugs would be recommended, 1, 5 are more likely to be treated by specialists than primary care physicians. These results may also be confounded by the fact that people with a lower socioeconomic status, who are more likely to receive more affordable drugs such as SUs, may have limited access to specialist care. 26 In addition, having a history of either macrovascular complications or chronic kidney disease was associated with a decreased likelihood of receiving an SGLT-2 inhibitor relative to an SU. Similarly, having a history of macrovascular complications was associated with a decreased likelihood of receiving a GLP-1 receptor agonist relative to an SU, and having a history of minor hypoglycaemic events was associated with a decreased likelihood of receiving a DPP-4 inhibitor relative to an SU. Again, these findings contradict the recommendations from recent clinical guidelines for individualized treatment based on patients' characteristics, [1] [2] [3] [4] [5] suggesting that non-medical reasons may play a significant part in treatment choices.
An increased likelihood of receiving an insulin prescription relative to SUs was strongly associated with very high HbA 1c levels (≥9.0%) and prescription by specialists (vs. primary care physicians). This is in line with the recommendations to initiate insulin in patients with very high HbA 1c levels, and with the fact that these patients are more likely to be managed in secondary rather than primary care. In the regional component of the multivariate analyses, regions were compared with Europe. With only one exception (DPP-4 inhibitor prescription in the Eastern Mediterranean region), prescription of SUs was more likely in every region than prescription of DPP-4 inhibitors, SGLT-2 inhibitors or insulin. This is likely to reflect the relatively high cost and low availability of these agents in some low-and medium-income countries compared with SUs. 14, 15 In Africa, prescription of SUs was much more likely than prescription of DPP-4 inhibitors (compared with Europe), again reflecting the relative costs of the two treatments. No patients in Africa received an SGLT-2 inhibitor.
These regional results are reflected in the descriptive assessment of treatment options shown in Table S4 ; the proportion of patients receiving an SU in combination with metformin was lower in Europe (18.3%) than in any other region, whereas the rate of DPP-4 inhibitor prescription with metformin was highest in the Eastern Mediterranean region (51.3%).
Together, these results suggest that many patients in large parts of the world are prescribed SUs rather than newer agents, such as DPP-4 inhibitors, SGLT-2 inhibitors or GLP-1 receptor agonists, when initiating second-line therapy, for economic and other non-medical reasons. This a real concern because these newer drugs likely to have a better cardiovascular safety profile than SUs. 27 Indeed, the use of SUs as second-line treatment (alone or in combination with metformin after first-line metformin monotherapy relative to continuing metformin monotherapy) has been shown to be associated with an increased risk of myocardial infarction and all-cause mortality. 28 Conversely, cardiovascular outcomes trials have shown that the use of SGLT-2 inhibitors and GLP-1 receptor agonists was associated with improved cardiovascular outcomes relative to placebo, particularly in patients at high cardiovascular risk. 18 Similarly, a large observational study identified a decreased likelihood of cardiovascular events in patients using SGLT-2 inhibitors compared with other glucose-lowering drugs. 29 
| Strengths and limitations
DISCOVER is a large and global study, which provides valuable and unique insights into treatment patterns in patients with type 2 diabetes globally, and also reflects variation in local practice because of differences in healthcare systems, physicians' demographics and training, site organization and recommendations from local clinical guidelines across included countries. However, only a limited number of countries could be included for practical reasons, and the focus was placed on lower-middle and upper-middle income countries for which no alternative data sources are currently available. The USA and Western European countries, such as Germany and the UK, were not included because established and comprehensive databases already exist (for example, the Diabetes Collaborative Registry in the USA, The Health Improvement Network and Clinical Practice Research Datalink databases in the UK, and the Disease Analyzer database in Germany) [30] [31] [32] [33] and have been used to assess treatment patterns in patients with type 2 diabetes in these countries. 13, 34, 35 The substantial efforts made before the start of the study to survey the types and locations of medical practices treating patients with type 2 diabetes have resulted in a heterogeneous patient population from diverse clinical settings. However, as for any observational study of this type, a fully representative patient sample was not possible to achieve. 9 
